Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwaj N, Norris T, Afghahi A, Frachioni A, Washington C, Dockery L, Elvin J, Graf RP, Moore KN. Richardson DL, et al. Among authors: washington c. Clin Cancer Res. 2024 Oct 15;30(20):4644-4653. doi: 10.1158/1078-0432.CCR-24-1225. Clin Cancer Res. 2024. PMID: 39078736 Free PMC article.
Olaparib in the treatment of ovarian cancer.
Washington CR, Richardson DL, Moore KN. Washington CR, et al. Future Oncol. 2019 Oct;15(30):3435-3449. doi: 10.2217/fon-2019-0271. Epub 2019 Sep 3. Future Oncol. 2019. PMID: 31478762 Review.
Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Tymon-Rosario J, et al. Among authors: washington c. Curr Opin Obstet Gynecol. 2023 Feb 1;35(1):6-14. doi: 10.1097/GCO.0000000000000838. Epub 2022 Dec 8. Curr Opin Obstet Gynecol. 2023. PMID: 36484278 Review.
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K, Castellano T, Washington C, Ting J, Surinach A, Kirshner C, Chhatwal J, Ayer T, Moore K. Sonawane K, et al. Among authors: washington c. Gynecol Oncol Rep. 2022 Dec 13;44:101121. doi: 10.1016/j.gore.2022.101121. eCollection 2022 Dec. Gynecol Oncol Rep. 2022. PMID: 36589508 Free PMC article.
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K, Castellano T, Washington C, Ting J, Surinach A, Kirshner C, Chhatwal J, Ayer T, Moore K. Sonawane K, et al. Among authors: washington c. Gynecol Oncol Rep. 2022 Nov 5;44(Suppl 1):101101. doi: 10.1016/j.gore.2022.101101. eCollection 2022 Dec. Gynecol Oncol Rep. 2022. PMID: 36506039 Free PMC article.
Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.
Castellano T, ElHabr AK, Washington C, Ting J, Zhang YJ, Musa F, Berksoy E, Moore K, Randall L, Chhatwal J, Ayer T, Leath CA 3rd. Castellano T, et al. Among authors: washington c. PLoS One. 2024 Jul 18;19(7):e0307282. doi: 10.1371/journal.pone.0307282. eCollection 2024. PLoS One. 2024. PMID: 39024212 Free PMC article.
318 results